| Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction … JM Hudson, A Loblaw, M McGuffin, HT Chung, CL Tseng, J Helou, ... Radiotherapy and Oncology, 110381, 2024 | 125 | 2024 |
| Vertebral compression fracture after spine stereotactic body radiation therapy: a review of the pathophysiology and risk factors S Faruqi, CL Tseng, C Whyne, M Alghamdi, J Wilson, S Myrehaug, ... Neurosurgery 83 (3), 314-322, 2018 | 125 | 2018 |
| Salvage stereotactic body radiotherapy (SBRT) following in-field failure of initial SBRT for spinal metastases I Thibault, M Campbell, CL Tseng, EG Atenafu, D Letourneau, E Yu, ... International Journal of Radiation Oncology* Biology* Physics 93 (2), 353-360, 2015 | 113 | 2015 |
| Spine stereotactic body radiotherapy: indications, outcomes, and points of caution CL Tseng, W Eppinga, R Charest-Morin, H Soliman, S Myrehaug, ... Global spine journal 7 (2), 179-197, 2017 | 103 | 2017 |
| Stereotactic body radiotherapy (SBRT) for oligometastatic spine metastases: an overview KL Zeng, CL Tseng, H Soliman, Y Weiss, A Sahgal, S Myrehaug Frontiers in oncology 9, 337, 2019 | 101 | 2019 |
| Imaging-based outcomes for 24 Gy in 2 daily fractions for patients with de novo spinal metastases treated with spine stereotactic body radiation therapy (SBRT) CL Tseng, H Soliman, S Myrehaug, YK Lee, M Ruschin, EG Atenafu, ... International Journal of Radiation Oncology* Biology* Physics 102 (3), 499-507, 2018 | 97 | 2018 |
| MR-guided radiation therapy: transformative technology and its role in the central nervous system Y Cao, CL Tseng, JM Balter, F Teng, HA Parmar, A Sahgal Neuro-oncology 19 (suppl_2), ii16-ii29, 2017 | 72 | 2017 |
| Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool PW Sperduto, BJ Deegan, J Li, KR Jethwa, PD Brown, N Lockney, K Beal, ... Neuro-oncology 20 (12), 1652-1660, 2018 | 64 | 2018 |
| Emerging technologies in stereotactic body radiotherapy L Ma, L Wang, CL Tseng, A Sahgal Chinese clinical oncology 6 (Suppl 2), S12-S12, 2017 | 60 | 2017 |
| Quantitative MRI biomarkers of stereotactic radiotherapy outcome in brain metastasis E Karami, H Soliman, M Ruschin, A Sahgal, S Myrehaug, CL Tseng, ... Scientific reports 9 (1), 19830, 2019 | 59 | 2019 |
| Mature local control and reirradiation rates comparing spine stereotactic body radiation therapy with conventional palliative external beam radiation therapy KL Zeng, S Myrehaug, H Soliman, ZA Husain, CL Tseng, J Detsky, ... International Journal of Radiation Oncology* Biology* Physics 114 (2), 293-300, 2022 | 52 | 2022 |
| Predictors of leptomeningeal disease following hypofractionated stereotactic radiotherapy for intact and resected brain metastases TK Nguyen, A Sahgal, J Detsky, EG Atenafu, S Myrehaug, CL Tseng, ... Neuro-oncology 22 (1), 84-93, 2020 | 50 | 2020 |
| Adverse radiation effect after hypofractionated stereotactic radiosurgery in 5 daily fractions for surgical cavities and intact brain metastases S Faruqi, M Ruschin, H Soliman, S Myrehaug, KL Zeng, Z Husain, ... International Journal of Radiation Oncology* Biology* Physics 106 (4), 772-779, 2020 | 48 | 2020 |
| Image-guided, linac-based, surgical cavity-hypofractionated stereotactic radiotherapy in 5 daily fractions for brain metastases H Soliman, S Myrehaug, CL Tseng, M Ruschin, A Hashmi, T Mainprize, ... Neurosurgery 85 (5), E860-E869, 2019 | 48 | 2019 |
| Magnetic resonance imaging assessment of spinal cord and cauda equina motion in supine patients with spinal metastases planned for spine stereotactic body radiation therapy CL Tseng, MS Sussman, EG Atenafu, D Letourneau, L Ma, H Soliman, ... International Journal of Radiation Oncology* Biology* Physics 91 (5), 995-1002, 2015 | 46 | 2015 |
| Pattern of relapse and dose received by the recurrent intraprostatic nodule in low-to intermediate-risk prostate cancer treated with single fraction 19 Gy high-dose-rate … LC Mendez, A Ravi, H Chung, CL Tseng, M Wronski, M Paudel, ... Brachytherapy 17 (2), 291-297, 2018 | 45 | 2018 |
| Quantitating interfraction target dynamics during concurrent chemoradiation for glioblastoma: a prospective serial imaging study J Stewart, A Sahgal, Y Lee, H Soliman, CL Tseng, J Detsky, Z Husain, ... International Journal of Radiation Oncology* Biology* Physics 109 (3), 736-746, 2021 | 42 | 2021 |
| MRI radiomics to differentiate between low grade glioma and glioblastoma peritumoral region N Malik, B Geraghty, A Dasgupta, PJ Maralani, M Sandhu, J Detsky, ... Journal of Neuro-Oncology 155, 181-191, 2021 | 36 | 2021 |
| Results of 15 Gy HDR-BT boost plus EBRT in intermediate-risk prostate cancer: analysis of over 500 patients K Martell, LC Mendez, HT Chung, CL Tseng, Y Alayed, P Cheung, S Liu, ... Radiotherapy and Oncology 141, 149-155, 2019 | 36 | 2019 |
| Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study CL Tseng, O Oxlade, D Menzies, A Aspler, K Schwartzman BMC Public Health 11, 1-16, 2011 | 35 | 2011 |
